Enzo Biochem, Inc.

    Enzo Biochem, Inc.

    NNYSE:ENZ
    0.55
    USD
    +0.02
    (+4.70%)
    0.81P/E
    2012 Y
    2013 Y
    2014 Y
    2015 Y
    2016 Y
    2017 Y
    2018 Y
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    2024 Y
    TTM
    Revenue per Share
    2.66
    2.37
    2.25
    2.15
    2.23
    2.27
    2.15
    1.71
    1.59
    2.44
    0.67
    0.63
    0.63
    0.56
    Basic EPS, GAAP
    -1.01
    -0.46
    -0.23
    -0.05
    0.98
    -0.05
    -0.22
    0.05
    -0.6
    0.16
    -0.38
    0.41
    -0.51
    -0.41
    Free Cash Flow per Basic Share
    -0.15
    -0.25
    -0.04
    -0.08
    1.15
    - -
    -0.06
    0.1
    -0.36
    0.01
    -0.34
    -0.75
    -0.52
    -0.29
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Book Value per Share
    -6.54
    -6.87
    -6.62
    -6.27
    -5.18
    -5.21
    -5.36
    -5.26
    -5.82
    -5.6
    -5.93
    -5.45
    -5.77
    -5.76
    Tangible Book Value per Share
    0.77
    0.42
    0.5
    0.64
    1.68
    1.69
    1.53
    1.64
    1.06
    1.26
    0.97
    1.6
    1.1
    0.9
    Basic Weighted Avg Shares
    39
    40
    43
    45
    46
    46
    47
    47
    48
    48
    49
    49
    51
    52
    Sales/Revenue/Turnover
    103
    94
    96
    98
    103
    105
    101
    81
    76
    118
    33
    31
    32
    29
    Operating Margin (%)
    -15.46
    -20.25
    -13.84
    -12.98
    -10.12
    -3
    -12.04
    -33.5
    -39.95
    0.59
    -53.69
    -79.64
    -38.75
    -34.14
    Depreciation Expense
    4
    5
    4
    4
    4
    4
    3
    3
    3
    3
    3
    3
    1
    1
    Net Income, GAAP
    -39
    -18
    -10
    -2
    45
    -3
    -10
    2
    -29
    8
    -18
    20
    -26
    -21
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    2.32
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    -38.09
    -19.46
    -10.4
    -2.34
    44.06
    -2.38
    -10.22
    3.07
    -37.52
    6.69
    -55.94
    65.32
    -81.73
    -73.25
    Working Capital
    21
    9
    16
    23
    71
    71
    63
    65
    36
    45
    30
    58
    45
    35
    LT Debt
    - -
    1
    1
    1
    1
    1
    - -
    4
    21
    19
    8
    3
    3
    2
    Total Equity
    49
    34
    37
    43
    90
    89
    81
    86
    58
    69
    54
    78
    56
    47
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    -15.29
    - -
    - -
    -32.1
    - -
    0.76
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    -17.51
    - -
    - -
    -1
    - -
    -3.2
    - -
    - -
    - -
    - -
    Return on Common Equity (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -

    Capital Structure

    USD

    •

    in mil. unless spec.
    Jul'24
    Oct'25
    Jan'25
    ST Debt
    1
    1
    1
    LT Borrowings
    - -
    - -
    - -
    LT Finance Leases
    2
    2
    2
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    52
    52
    52
    Market Capitalization
    53
    54
    31

    Working Capital

    USD

    •

    in mil. unless spec.
    Jul'24
    Oct'25
    Jan'25
    Total Current Assets
    70
    60
    52
    Cash, Cash Equivalents & STI
    52
    48
    40
    Accounts Receivable, Net
    4
    4
    4
    Inventories
    7
    6
    6
    Total Current Liabilities
    25
    23
    17
    Payables & Accruals
    6
    12
    5
    ST Debt
    1
    1
    1
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    10.24%
    -3.93%
    -28.49%
    Free Cash Flow
    -541.24%
    -970.52%
    -28.98%
    Net Income, GAAP
    -422.14%
    -429%
    -228.54%
    Sales/Revenue/Turnover
    -4.01%
    -5.17%
    2.72%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    7
    8
    7
    -20
    31
    2024
    8
    9
    8
    8
    32
    2025
    6
    7
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    -0.22
    -0.23
    -0.31
    - -
    0.41
    2024
    -0.13
    -0.06
    -0.06
    - -
    -0.51
    2025
    -0.06
    -0.03
    - -
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • globenewswire.com

      Enzo Biochem, Inc. To be Acquired by Battery Ventures in All-Cash Transaction

    • globenewswire.com

      Enzo Biochem Reports Third Quarter Fiscal Year 2025 Results

    • globenewswire.com

      Enzo Biochem, Inc. Announces Review of Strategic Alternatives after Receiving Multiple Inquiries Regarding a Potential Transaction

    • zacks.com

      The Zacks Analyst Blog AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment

    • globenewswire.com

      Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX

    • globenewswire.com

      Enzo Biochem Reports Second Quarter Fiscal Year 2025 Results

    • globenewswire.com

      Enzo Biochem Receives Notice of Non-Compliance with New York Stock Exchange Listing Rules

    • zacks.com

      ENZ Stock Falls Post Q1 Earnings Amid Revenue and Demand Challenges

    • globenewswire.com

      Enzo Biochem Reports First Quarter Fiscal Year 2025 Results and Provides a Company Update

    • zacks.com

      ENZ Stock Up Following FY24 Earnings Uptick, Gross Margin Expands

    • globenewswire.com

      Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend

    • reuters.com

      Enzo Biochem to pay $4.5 mln for failing to safeguard patient data

    • seekingalpha.com

      Enzo Biochem: Is This Time Finally Different?

    • zacks.com

      Zacks Initiates Coverage of Enzo Biochem With Neutral Recommendation

    • zacks.com

      Enzo Biochem (ENZ) Q3 Earnings Improve Y/Y, Gross Margin Up

    • globenewswire.com

      Enzo Biochem Reports Third Quarter Fiscal 2024 Results and Provides Business Update

    • globenewswire.com

      Enzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business Update

    • globenewswire.com

      Enzo Biochem Reports Results of its Annual Meeting of Shareholders and Officer Appointments

    • globenewswire.com

      ENZO BIOCHEM REPORTS FIRST QUARTER FISCAL 2024 RESULTS AND PROVIDES BUSINESS UPDATE

    • globenewswire.com

      Steven J. Pully Appointed to Enzo Biochem's Board of Directors